RESUMEN
Paragonimiasis is a parasite infection caused by several species of Paragonimus, a trematode that is transmitted through the consumption of raw or undercooked crabs and that has been found in the subtropical areas of America, Asia and Africa. This infection mainly affects the lungs, causing clinical and radiological manifestations very similar to pulmonary tuberculosis, so it should always be included in the differential diagnosis. We present the case of a 7-year-old school patient, hospitalized with the diagnosis of pulmonary paragonimiasis, who had a favorable evolution after receiving treatment with triclabendazole.
La paragonimiasis es una parasitosis provocada por varias especies de Paragonimus, un trematodo que se transmite a través del consumo de cangrejos poco cocidos o crudos y que se ha encontrado en áreas tropicales y subtropicales de América, Asia y África. Esta infección afecta, principalmente, los pulmones y provoca manifestaciones clínicas y radiológicas muy similares a la tuberculosis pulmonar, por lo cual siempre debe incluirse dentro del diagnóstico diferencial. Se presenta el caso de una niña escolar de 7 años de edad, hospitalizada con el diagnóstico de paragonimiasis pulmonar, quien presentó evolución favorable luego de recibir tratamiento con triclabendazol.
Asunto(s)
Enfermedades Pulmonares Parasitarias/diagnóstico , Paragonimiasis/diagnóstico , Triclabendazol/administración & dosificación , Animales , Antiplatelmínticos/administración & dosificación , Niño , Femenino , Humanos , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Enfermedades Pulmonares Parasitarias/parasitología , Paragonimiasis/tratamiento farmacológico , Paragonimus/aislamiento & purificaciónRESUMEN
A 30-year-old male, from a subtropical region of Ecuador, was hospitalized with a 5-year history of persistent cough with rusty brown sputum, chest pain, and progressive dyspnea. The patient underwent thoracic surgery 3 years ago for pleural effusion and subsequently received a 9-month regimen treatment of tuberculosis. However, there was no clinical resolution and symptoms became progressively worse. A chest radiograph and computerized tomography scan showed several small nodules in both lungs. Eggs of Paragonimus spp. were observed in sputum smears, but the smears were negative for acid-fast bacilli. Molecular characterization of eggs by the internal transcribed spacer-2 regions identified them as Paragonimus mexicanus The patient was treated with praziquantel and tested negative parasitologically for 12 months. There was clinical resolution of the cough and expectoration, but dyspnea and chest pain persisted.
Asunto(s)
Enfermedades Pulmonares Parasitarias/patología , Paragonimiasis/epidemiología , Paragonimiasis/patología , Paragonimus/aislamiento & purificación , Enfermedades Pleurales/patología , Adulto , Animales , Ecuador/epidemiología , Humanos , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Enfermedades Pulmonares Parasitarias/parasitología , Masculino , Paragonimiasis/tratamiento farmacológico , Paragonimus/clasificación , Enfermedades Pleurales/tratamiento farmacológico , Enfermedades Pleurales/parasitología , Praziquantel/uso terapéuticoRESUMEN
A review of national and international publications on paragonimiasis in Ecuador, epidemiological records from the Ministry of Public Health and unpublished research data was conducted to summarise the current status of the parasite/disease. The purpose of the review is to educate physicians, policy-makers and health providers on the status of the disease and to stimulate scientific investigators to conduct further research. Paragonimiasis was first diagnosed in Ecuador 94 years ago and it is endemic to both tropical and subtropical regions in 19 of 24 provinces in the Pacific Coast and Amazon regions. Paragonimus mexicanus is the only known species in the country, with the mollusc Aroapyrgus colombiensis and the crabs Moreirocarcinus emarginatus, Hypolobocera chilensis and Hypolobocera aequatorialis being the primary and secondary intermediate hosts, respectively. Recent studies found P. mexicanus metacercariae in Trichodactylus faxoni crabs of the northern Amazon. Chronic pulmonary paragonimiasis is commonly misdiagnosed and treated as tuberculosis and although studies have demonstrated the efficacy of praziquantel and triclabendazole for the treatment of human infections, neither drug is available in Ecuador. Official data recorded from 1978-2007 indicate an annual incidence of 85.5 cases throughout the 19 provinces, with an estimated 17.2% of the population at risk of infection. There are no current data on the incidence/prevalence of infection, nor is there a national control programme.
Asunto(s)
Enfermedades Pulmonares Parasitarias/epidemiología , Metacercarias/aislamiento & purificación , Paragonimiasis/epidemiología , Paragonimus/clasificación , Animales , Antihelmínticos/uso terapéutico , Astacoidea/parasitología , Braquiuros/parasitología , Enfermedad Crónica , Ecuador/epidemiología , Humanos , Enfermedades Pulmonares Parasitarias/diagnóstico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Enfermedades Desatendidas/epidemiología , Paragonimiasis/diagnóstico , Paragonimiasis/tratamiento farmacológicoRESUMEN
A review of national and international publications on paragonimiasis in Ecuador, epidemiological records from the Ministry of Public Health and unpublished research data was conducted to summarise the current status of the parasite/disease. The purpose of the review is to educate physicians, policy-makers and health providers on the status of the disease and to stimulate scientific investigators to conduct further research. Paragonimiasis was first diagnosed in Ecuador 94 years ago and it is endemic to both tropical and subtropical regions in 19 of 24 provinces in the Pacific Coast and Amazon regions. Paragonimus mexicanus is the only known species in the country, with the mollusc Aroapyrgus colombiensis and the crabs Moreirocarcinus emarginatus, Hypolobocera chilensis and Hypolobocera aequatorialis being the primary and secondary intermediate hosts, respectively. Recent studies found P. mexicanus metacercariae in Trichodactylus faxoni crabs of the northern Amazon. Chronic pulmonary paragonimiasis is commonly misdiagnosed and treated as tuberculosis and although studies have demonstrated the efficacy of praziquantel and triclabendazole for the treatment of human infections, neither drug is available in Ecuador. Official data recorded from 1978-2007 indicate an annual incidence of 85.5 cases throughout the 19 provinces, with an estimated 17.2% of the population at risk of infection. There are no current data on the incidence/prevalence of infection, nor is there a national control programme.
Asunto(s)
Animales , Humanos , Enfermedades Pulmonares Parasitarias/epidemiología , Metacercarias/aislamiento & purificación , Paragonimiasis/epidemiología , Paragonimus/clasificación , Antihelmínticos/uso terapéutico , Astacoidea/parasitología , Braquiuros/parasitología , Enfermedad Crónica , Ecuador/epidemiología , Enfermedades Pulmonares Parasitarias/diagnóstico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Enfermedades Desatendidas/epidemiología , Paragonimiasis/diagnóstico , Paragonimiasis/tratamiento farmacológicoRESUMEN
Paragonimiasis is a food-borne zoonosis caused by a trematode of the genus Paragonimus(1,2). Infestation is rare in Spain, but the influx of people from endemic areas should make us keep this condition in the differential diagnosis of our patients(2,5). We report the case a patient from Ecuador and resident in Spain for 7 years with active pulmonary tuberculosis on arrival in Spain and later diagnosed with of pulmonary paragonimiasis due to persistent haemoptysis. The diagnosis was established by surgical lung specimen showing granulomas containing parasite eggs and the macroscopic view of the fluke within a lung cavity. Initial tuberculosis treatment and current treatment with praziquantel controlled both conditions.
Asunto(s)
Enfermedades Pulmonares Parasitarias/diagnóstico , Paragonimiasis/diagnóstico , Adulto , Animales , Antihelmínticos/uso terapéutico , Antituberculosos/uso terapéutico , Caulobacteraceae/aislamiento & purificación , Diagnóstico Tardío , Ecuador/etnología , Etambutol/uso terapéutico , Parasitología de Alimentos , Infecciones por Bacterias Gramnegativas/complicaciones , Infecciones por Bacterias Gramnegativas/microbiología , Granuloma/etiología , Granuloma/parasitología , Hemoptisis/etiología , Humanos , Isoniazida/uso terapéutico , Enfermedades Pulmonares Parasitarias/complicaciones , Enfermedades Pulmonares Parasitarias/diagnóstico por imagen , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Enfermedades Pulmonares Parasitarias/parasitología , Masculino , Paragonimiasis/complicaciones , Paragonimiasis/diagnóstico por imagen , Paragonimiasis/tratamiento farmacológico , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/microbiología , Praziquantel/uso terapéutico , Pirazinamida/uso terapéutico , Radiografía , Rifampin/administración & dosificación , España , Tuberculosis Pulmonar/complicaciones , Tuberculosis Pulmonar/diagnóstico por imagen , Tuberculosis Pulmonar/tratamiento farmacológicoRESUMEN
La paragonimiasis es una antropozoonosis de transmisión alimentaria causada por tremátodos del género Paragonimus siendo P. Westwermanii el que más infecta al hombre. La infección del humano ocurre posterior a la ingesta de crustáceos de agua dulce mal cocinados, infectados con metacercarias. La gravedad y la progresión de los síntomas dependen de la fase y del número de parásitos presentes. La fase de infección pulmonar está caracterizada por tos, hemoptisis, dolor torácico, pérdida de peso y anormalidades radiológicas. Dado la sintomatología respiratoria y los hallazgos radiológicos inespecíficos; la tuberculosis pulmonar es el principal diagnostico diferencial a considerar. El diagnóstico se basa en la demostración del paragonimus por medios parasitológicos, en algunos casos como paragonimiasis extra pulmonar o en otras circunstancias cuando los métodos bacteriológicos fallan es necesario la realización estudios serológicos. El prazicuantel actualmente es considerado el tratamiento de elección.
Asunto(s)
Enfermedades Transmitidas por los Alimentos , Paragonimiasis/diagnóstico , Paragonimiasis/epidemiología , Paragonimiasis/tratamiento farmacológico , Pruebas Serológicas , Infecciones por Trematodos , ZoonosisRESUMEN
The authors present a case from a 59 years old white female Brazilian patient, based in Salvador-Bahia, Brazil's northeastern side area, who experienced irritative cough and progressive dyspnea, and, after 18 months, was admitted to a hospital with respiratory insufficiency. The physical exam showed diffuse rales in both hemithoraces. Initial leukogram showed 14,400 cells/microL with 14% of eosinophils and chest X-ray showed peribronchovascular infiltrate, predominating in the lower half of the lung fields, and small opaque nodules. The high-resolution computed tomography scan of the chest (HRCT) presented compatible pattern with airways disease, especially from the small airways, with air trapping, tree sprouting images, central lobular nodules and bronchiectasis, making the results compatible with bronchiolitis and bronchiectasis. The transbroncho biopsy unveiled granulomatous lesion with necrosis, where was noticed a structure compatible to a parasitic case, and the research of the parasite eggs in the sputum was positive to paragonimus. After the praziquantel use, the patient presented a thick ferruginous expectoration and the result for BAAR examination was positive. The PCR exam and the sputum culture confirmed M. tuberculosis, and then the treatment for M. tuberculosis was initiated. The authors warn that this infection may have been a consequence of economics globalization process, where the importation of parasitized crustaceans might be the cause. However, there is the need of an accurate examination for the possibility of paragonimus specimens in this area of Brazil.
Asunto(s)
Enfermedades Pulmonares Parasitarias/epidemiología , Paragonimiasis/epidemiología , Animales , Antihelmínticos/uso terapéutico , Brasil/epidemiología , Femenino , Humanos , Enfermedades Pulmonares Parasitarias/diagnóstico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Persona de Mediana Edad , Paragonimiasis/diagnóstico , Paragonimiasis/tratamiento farmacológico , Paragonimus/aislamiento & purificación , Praziquantel/uso terapéuticoRESUMEN
The authors present a case from a 59 years old white female Brazilian patient, based in Salvador-Bahia, Brazil's northeastern side area, who experienced irritative cough and progressive dyspnea, and, after 18 months, was admitted to a hospital with respiratory insufficiency. The physical exam showed diffuse rales in both hemithoraces. Initial leukogram showed 14,400 cells/mL with 14 percent of eosinophils and chest X-ray showed peribronchovascular infiltrate, predominating in the lower half of the lung fields, and small opaque nodules. The high-resolution computed tomography scan of the chest (HRCT) presented compatible pattern with airways disease, especially from the small airways, with air trapping, tree sprouting images, central lobular nodules and bronchiectasis, making the results compatible with bronchiolitis and bronchiectasis. The transbroncho biopsy unveiled granulomatous lesion with necrosis, where was noticed a structure compatible to a parasitic case, and the research of the parasite eggs in the sputum was positive to paragonimus. After the praziquantel use, the patient presented a thick ferruginous expectoration and the result for BAAR examination was positive. The PCR exam and the sputum culture confirmed M. tuberculosis, and then the treatment for M. tuberculosis was initiated. The authors warn that this infection may have been a consequence of economics globalization process, where the importation of parasitized crustaceans might be the cause. However, there is the need of an accurate examination for the possibility of paragonimus specimens in this area of Brazil.
Asunto(s)
Animales , Femenino , Humanos , Persona de Mediana Edad , Enfermedades Pulmonares Parasitarias/epidemiología , Paragonimiasis/epidemiología , Antihelmínticos/uso terapéutico , Brasil/epidemiología , Enfermedades Pulmonares Parasitarias/diagnóstico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Paragonimiasis/diagnóstico , Paragonimiasis/tratamiento farmacológico , Paragonimus/aislamiento & purificación , Praziquantel/uso terapéuticoRESUMEN
A well-tolerated single-day treatment regimen is required for the community-based treatment of pulmonary paragonimiasis. To identify an optimal single-day treatment regimen, an open clinical trial was performed to compare the efficacy of 2 single-day regimens of triclabendazole. From 1991 to 1993, a total of 154 Ecuadorian patients were allocated to receive either a single dose or 2 doses of 10 mg/kg triclabendazole. Treatment with both regimens was associated with a rapid parasitological response (determined by clearance of Paragonimus eggs from sputum), resolution of most clinical symptoms and radiological signs, and only mild adverse effects. At 3 months after treatment, the cure rate (clearance of eggs from sputum) was 90.9% in the 2-dose group and 84.4% in the single-dose group. Re-treatment with a second 2-dose regimen was curative in all remaining patients by 1 year of follow-up. Our findings show that both single-day treatment regimens of triclabendazole were highly effective in the treatment of pulmonary paragonimiasis and suggest that patients should be re-examined at 3 months to determine the need for repeat treatment.
Asunto(s)
Antihelmínticos/administración & dosificación , Bencimidazoles/administración & dosificación , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Paragonimiasis/tratamiento farmacológico , Adolescente , Adulto , Anciano , Antihelmínticos/efectos adversos , Antihelmínticos/uso terapéutico , Bencimidazoles/efectos adversos , Bencimidazoles/uso terapéutico , Niño , Preescolar , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Enfermedades Pulmonares Parasitarias/parasitología , Masculino , Persona de Mediana Edad , Paragonimiasis/parasitología , Recuento de Huevos de Parásitos , Esputo/parasitología , Resultado del Tratamiento , TriclabendazolRESUMEN
An open clinical trial to determine the efficacy and tolerability of postprandial doses of triclabendazole against Paragonimus mexicanus in 62 patients with pulmonary paragonimiasis from the Ecuadorian Amazon region was performed. Praziquantel was used as therapeutic control. Patients were allocated at random to the following 4 therapeutic regimens: triclabendazole, 5 mg/kg once daily for 3 d (16 patients), 10 mg/kg twice on one day (15 patients), and 10 mg/kg in a single dose (16 patients), and praziquantel, 25 mg/kg thrice daily for 3 d (15 patients). Clinical tolerance, based on the frequency and severity of adverse reactions, was superior in all 3 triclabendazole regimens to that of praziquantel. No alteration was observed in hepato-renal functions or haematological values. The clinical symptoms resolved at a comparable rate in all 4 treatment groups. A more rapid parasitological response to treatment, as determined by the reduction in the average number of parasite eggs found in sputum, was seen in patients treated with triclabendazole than with praziquantel. By day 90, 60 patients had no egg detected in their sputum; 2 patients, treated with a single dose of 10 mg/kg, had a few and were re-treated with triclabendazole (5 mg daily for 3 d). On day 365, none of the patients had eggs in their sputum. Triclabendazole can be recommended as an alternative drug of choice for the treatment of pulmonary paragonimiasis; it is as effective as praziquantel in clearing infections and better tolerated.
Asunto(s)
Antihelmínticos/uso terapéutico , Bencimidazoles/uso terapéutico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Paragonimiasis/tratamiento farmacológico , Adolescente , Adulto , Anticestodos/uso terapéutico , Niño , Ecuador/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Recuento de Huevos de Parásitos/métodos , Recuento de Huevos de Parásitos/estadística & datos numéricos , Praziquantel/uso terapéutico , Resultado del Tratamiento , TriclabendazolRESUMEN
The cases of two Costa Rican children with pericarditis due to Paragonimus mexicanus are reported. Clinical, epidemiological and laboratory tests are consistent with the disease. Treatment with praziquantel and bitheonol was associated with clinical cure. A review of the literature and a suggested table of diagnostic criteria are included.
Asunto(s)
Paragonimiasis , Pericarditis/parasitología , Antiplatelmínticos/uso terapéutico , Bitionol/uso terapéutico , Preescolar , Costa Rica , Eosinofilia , Femenino , Humanos , Paragonimiasis/diagnóstico , Paragonimiasis/tratamiento farmacológico , Derrame Pericárdico , Pericarditis/diagnóstico , Pericarditis/tratamiento farmacológico , Praziquantel/uso terapéuticoRESUMEN
Dentro del estudio clínico-terapéutico para determinar la posología efectiva de triclabendazole contra Paragonimus recibieron tratamiento con esta droga tres pacientes ecuatorianos con paragonimiasis pulmonar que fracasaron al tratamiento con emetina más cloroquina, bithienol y praziquantel individualmente. En todos los síntomas de tos, expectoración herrumbrosa y la presencia de huevos de Paragonimus mexicanus en esputo estaban presentes antes del tratamiento. Dos pacientes recibieron tricabendazole a 10mg/kg en dosis única, y el tercero a 5mg/kg una vez al día por tres días . El seguimiento hasta el año 1 postratamiento demostró la desaparición de la sintomatología y cura parasitológica. Los pacientes no presentaron efectos secundarios al fármaco.
Asunto(s)
Humanos , Femenino , Adolescente , Adulto , Bencimidazoles/administración & dosificación , Bitionol/uso terapéutico , Emetina/uso terapéutico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Paragonimiasis/tratamiento farmacológico , Praziquantel/uso terapéutico , EcuadorRESUMEN
La paragonimiasis es una enfermedad parasitaria causada por un tremátodo del género Paragonímus. Es endémica en Corea, Japón y China. En América Latina se han identificado algunos casos. En México hay 6 casos en la literatura revisada. El caso que nos ocupa es el de mujer de 41 años que ingresó al Instituto Nacional de Enfermedades Repiratorias con tos crónica, hemoptisis y pérdida de peso, a la que se practicó lobectomía superior derecha. En el estudio histopatológico se observaron lesiones granulomatosas que contenían huevecillos de Paragonimus
Asunto(s)
Humanos , Femenino , Adulto , Paragonimiasis , Paragonimiasis/cirugía , Paragonimiasis/parasitología , Paragonimiasis/patología , Paragonimiasis/tratamiento farmacológico , Paragonimus , Praziquantel/uso terapéutico , México , NeumonectomíaAsunto(s)
Isoquinolinas/uso terapéutico , Enfermedades Pulmonares Parasitarias/tratamiento farmacológico , Paragonimiasis/tratamiento farmacológico , Praziquantel/uso terapéutico , Adolescente , Heces/parasitología , Humanos , Enfermedades Pulmonares Parasitarias/etiología , Masculino , Paragonimiasis/parasitología , Paragonimus/aislamiento & purificación , Esputo/parasitologíaRESUMEN
Se describe el primer caso colombiano de Paragonimiasis humana, comprobado histopatologicamente, que afecto principalmente la base del pulmon derecho, comprometido por vecindad al hemidiafragma derecho y al higado. La enfermedad del paciente fue, muy probablemente, adquirida en Mesetas, Meta y tuvo una evolucion aproximada de 4 anos; el paciente fallecio durante el post-operatorio inmediato a la reseccion de las lesiones pleuro-pulmonares y hepaticas. La sintomatologia fue la de una neumopatia cronica con tos hemoptica y hemoptisis. A pesar de multiples baciloscopias, reiterativamente negativas para bacilo tuberculoso, el paciente se le diagnostico y trato para Tuberculosis Pulmonar. En nuestro medio, la Paragonimiasis debe ser incluida dentro del diagnostico diferencial de las neumopatias cronicas con tos hemoptoica y hemoptisis